Neeraj Agarwal, MD, FASCO, on mCRPC: Talazoparib Plus Enzalutamide as First-Line Treatment

0 seconds of 0 secondsVolume 90%

00:00

Neeraj Agarwal, MD, FASCO, on mCRPC: Talazoparib Plus Enzalutamide as First-Line Treatment

2025 ASCO GU

Neeraj Agarwal, MD, FASCO, of Huntsman Cancer Institute, presents data from cohort 1 of the phase III TALAPRO-2 trial—final overall survival data, an update on radiographic progression–free survival, and safety follow-up—which included patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair gene alterations (Abstract LBA18).

William Aronson, MD, on a Specialized Diet in Men on Active Surveillance for Prostate Cancer

William Aronson, MD, of the VA Greater Los Angeles Healthcare System, discusses findings from the CAPFISH-3 trial, which investigated whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules decreased Ki-67 levels in men with prostate cancer on active surveillance (Abstract 312).

Prostate Cancer

Supportive Care

The ASCO Post Staff

Benjamin Maughan, MD, PharmD, on Exercise Therapy for Patients With Advanced Prostate Cancer

Benjamin Maughan, MD, PharmD, of Huntsman Cancer Institute, discusses the effects of a 12-week, structured, guided exercise program called Personal Optimism With Exercise Recovery (POWER) on fatigue and peak aerobic exercise capacity in patients with advanced prostate cancer receiving androgen-deprivation therapy (Abstract 120).

Prostate Cancer

The ASCO Post Staff

Michael Schweizer, MD: EZH2 Inhibitor Plus Enzalutamide in mCRPC

Michael Schweizer, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses findings from a randomized dose-expansion study of the investigational EZH2 inhibitor mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA138).

Prostate Cancer

The ASCO Post Staff

Karim Fizazi, MD, PhD, on HRR-Deficient mCRPC: Final Overall Survival in TALAPRO-2

Karim Fizazi, MD, PhD, of Institut Gustave Roussy, University of Paris-Saclay, reviews final overall survival results from cohort 2 of the phase III TALAPRO-2 trial, which investigated the combination of talazoparib and enzalutamide in patients with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA141).

Prostate Cancer

The ASCO Post Staff

Omid Yazdanpanah, MD, on Metastatic Castration-Resistant Prostate Cancer: LuPSMA With or Without ARPIs

Omid Yazdanpanah, MD, of the University of California, Irvine, presents findings from a secondary analysis of the VISION trial, which compared the efficacy and safety of LuPSMA in patients treated with vs without concomitant androgen receptor pathway inhibitors (ARPIs) (Abstract 121).

Apr

Today In Oncology

Neeraj Agarwal, MD, FASCO, on mCRPC: Talazoparib Plus Enzalutamide as First-Line Treatment

Related Videos

William Aronson, MD, on a Specialized Diet in Men on Active Surveillance for Prostate Cancer

Benjamin Maughan, MD, PharmD, on Exercise Therapy for Patients With Advanced Prostate Cancer

Michael Schweizer, MD: EZH2 Inhibitor Plus Enzalutamide in mCRPC

Karim Fizazi, MD, PhD, on HRR-Deficient mCRPC: Final Overall Survival in TALAPRO-2

Omid Yazdanpanah, MD, on Metastatic Castration-Resistant Prostate Cancer: LuPSMA With or Without ARPIs

TB Vaccination Could Enhance BCG Response in Patients With Non-Muscle-Invasive Bladder Cancer, Study Finds

Study Finds Standard Chemoradiation Therapy Superior to Deintensification Approaches for HPV-Related Oropharyngeal Cancer

Daily Physical Activity Even at Light Intensities May Reduce Cancer Risk

Could Brain Imaging Plus VR Minimize Cancer-Related Pain

Presymptomatic Awareness of BRCA1/BRCA2 Status and Outcomes in Ovarian Cancer